文献速递精神分裂症与精神病性障碍

精神分裂症脑脊液与血清内源性大麻素及鞘脂生物标志物的机器学习识别

Identification of fluid endocannabinoid and sphingolipid biomarkers in schizophrenia. A machine learning approach toward clinical value.
PubMed 文献 · Mol Psychiatry · 2026-10-30

本研究首次在匹配的脑脊液和血清样本中全面交叉分析未用药和已用药精神分裂症患者及健康志愿者的内源性大麻素与鞘脂,并应用IDEARS机器学习平台识别判别特征。脑脊液AUC在未用药患者为0.87、已用药患者为0.94,血清AUC分别为0.87和0.90;未用药患者脑脊液中anandamide显著升高(q=0.010),且鞘脂d18:2骨架升高在脑脊液与血清中保守。结果支持内源性大麻素系统与鞘脂失衡参与精神分裂症,机器学习有助于生物标志物发现与分层。

要点

  • 脑脊液和血清内源性大麻素与鞘脂组合在机器学习下可区分精神分裂症与健康对照。
  • 未用药患者脑脊液anandamide显著升高(q=0.010),血清中亦被IDEARS列为前十特征。
  • 未用药患者脑脊液与血清中d18:2鞘脂升高保守,提示外周替代标志物潜力。

核心结论

  • 内源性大麻素系统与鞘脂代谢失衡参与精神分裂症,机器学习支持其作为客观生物标志物的潜力。
  • 脑脊液与血清脂质特征可区分精神分裂症患者与健康志愿者,并可能用于治疗监测。

研究设计与样本

  • 研究纳入未用药精神分裂症患者(SCZnaïve,n=49)、已用药患者(SCZtreat,n=56)和健康志愿者(HVs,n=51),采集匹配的脑脊液与血清样本。
  • 使用液相色谱-串联质谱定量内源性大麻素、N-酰基乙醇胺、神经酰胺和鞘磷脂,并应用IDEARS机器学习平台识别判别特征。

主要发现

  • 脑脊液AUC在SCZnaïve为0.87、SCZtreat为0.94;血清AUC在SCZnaïve为0.87、SCZtreat为0.90。
  • Anandamide是SCZnaïve患者脑脊液中最主要的判别特征,水平较HVs显著升高(q=0.010)。
  • IDEARS将anandamide列为SCZnaïve患者血清前十特征,但常规统计未达显著。
  • SCZnaïve患者脑脊液与血清中d18:2骨架鞘脂均升高(q<0.05),提示外周替代标志物潜力。
  • 已用药患者呈现治疗相关神经酰胺模式:C16-C18升高、长链(>C24)降低,可能反映抗精神病药代谢效应。

关键数值与推荐

  • 脑脊液AUC:SCZnaïve=0.87,SCZtreat=0.94;血清AUC:SCZnaïve=0.87,SCZtreat=0.90。
  • SCZnaïve患者脑脊液anandamide较HVs升高,q=0.010。
  • SCZnaïve患者脑脊液与血清d18:2鞘脂升高,q<0.05。

临床怎么用

  • 脑脊液与血清脂质标志物组合有望辅助精神分裂症的客观诊断与治疗分层。
  • Anandamide和d18:2鞘脂可作为候选外周标志物,但需进一步验证后用于临床。
  • 治疗相关神经酰胺模式可能用于监测抗精神病药的代谢效应。

局限性

  • 原文未报告样本量以外的多中心验证或独立复制队列。
  • 血清anandamide在常规统计下未达显著,其判别价值依赖机器学习模型。
  • 治疗相关神经酰胺模式为观察性发现,不能推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schizophrenia (SCZ) diagnosis relies on subjective clinical evaluation, with symptoms often overlapping between psychiatric conditions, hindering early intervention, and creating an urgent need for objective, accessible biomarkers. Lipids, especially endocannabinoid system (ECS) and sphingolipid metabolism members, are promising candidates given their implication in SCZ pathogenesis and measurability in accessible biofluids, with minimally invasive procedures. Our study conducted the first comprehensive crossover of endocannabinoids (eCBs) and sphingolipids in matched cerebrospinal fluid (CSF) and serum samples from antipsychotic-naïve SCZ patients (SCZnaïve, n = 49), antipsychotic-treated patients (SCZtreat, n = 56), and healthy volunteers (HVs, n = 51). The machine learning Integrated Disease Explanation and Risk Scoring (IDEARS) platform was applied to eCBs, N-acylethanolamines, ceramides, and sphingomyelins quantified using liquid chromatography-tandem mass spectrometry, identifying key discriminatory features across biofluids and conditions (CSF AUC: SCZnaïve = 0.87, SCZtreat = 0.94; serum AUC: SCZnaïve = 0.87, SCZtreat = 0.90). Anandamide emerged as the top CSF feature in SCZnaïve patients, showing significantly elevated levels (q = 0.010) compared to HVs. Notably, though not statistically significant under conventional statistics, IDEARS identified anandamide as a top ten serum feature. Additionally, elevated sphingadiene backbone (d18:2) sphingolipids were conserved between the CSF and serum of SCZnaïve (q < 0.05), highlighting their potential as peripheral surrogate markers. Treatment-specific ceramide patterns were also evident, with elevated C16-C18 and reduced long-chain (>C24) species potentially reflecting antipsychotic metabolic effects. Our results support the involvement of the ECS and sphingolipid imbalances in SCZ, highlighting the potential of machine learning for novel biomarker discovery, including stratification across biofluids, and therapeutic monitoring toward more objective psychiatric care.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hoffmann AE, Allwright M, Guennewig B, et al. Identification of fluid endocannabinoid and sphingolipid biomarkers in schizophrenia. A machine learning approach toward clinical value. Mol Psychiatry. 2026. PMID: 42963368. doi:10.1038/s41380-026-03933-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。